A Study to Evaluate BMS-986470
Phase 1/2
184
about 3.3 years
18+
13 sites in AL, CA, CT +6
What this study is about
This trial is testing a treatment called BMS-986470 in people with healthy volunteers and sickle cell disease. The goal is to see if this treatment is safe, how it works in the body, and if it has any effect on pH levels or food intake.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take BMS-986470
- 2.Take Famotidine
- 3.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
famotidine
oral (Oral Tablet)
Primary: Number of deaths, Number of participants with AEs leading to discontinuation, Number of participants with AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteria, Number of participants with adverse events (AEs), Number of participants with serious adverse events (SAEs)
Secondary: Area under the concentration-time curve (AUC), Change from baseline in markers of RBC lysis: absolute reticulocyte count, Change from baseline in markers of RBC lysis: aspartate aminotransferase (AST), Change from baseline in markers of RBC lysis: haptoglobin, Change from baseline in markers of RBC lysis: indirect bilirubin, Change from baseline in markers of RBC lysis: lactate dehydrogenase (LDH), Change from baseline in markers of RBC lysis: reticulocyte percentage of RBCs, Change from baseline in markers of RBC lysis: total bilirubin